About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.440 -0.210 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 647,883
Open 5.740
Bid (Size) 5.400 (100)
Ask (Size) 5.590 (100)
Prev. Close 5.650
Today's Range 5.345 - 5.777
52wk Range 4.250 - 13.68
Shares Outstanding 28,919,810
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
From Candel Therapeutics
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
+8.4%
+8.4%
3 Month
-2.2%
-2.2%
6 Month
+9.0%
+9.0%
1 Year
-39.5%
-39.5%

More News

Read More
News headline image
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗
Via Stocktwits
News headline image
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
From Candel Therapeutics
Via GlobeNewswire
News headline image
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
Via Benzinga
News headline image
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Reports 88 Percent Q2 Loss Drop ↗
Via The Motley Fool
News headline image
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
From Candel Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?
Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
What is the current price of Candel Therapeutics, Inc. - Common Stock?
The current price of Candel Therapeutics, Inc. - Common Stock is 5.440
When was Candel Therapeutics, Inc. - Common Stock last traded?
The last trade of Candel Therapeutics, Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
The market capitalization of Candel Therapeutics, Inc. - Common Stock is 157.32M
How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
Candel Therapeutics, Inc. - Common Stock has 157M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.